The successful outcome of the Phase 2a study for PRAX-628 in treating epilepsy patients with PPR is a significant positive development for Praxis Precision Medicines. This result not only demonstrates the drug's potential efficacy but also positions the company favorably in the CNS disorder treatment market. Given the 100% response rate, investor optimism is likely to increase, potentially leading to a positive short-term impact on PRAX's stock price.